Valuation Fundamentals for Biotechnology Companies

For valuation professionals, valuing biotechnology companies often poses distinct challenges, including high scientific uncertainty, binary regulatory outcomes, dependence on funding, and, in many cases, limited operating history.

This webcast is designed for professionals who perform or review biotech valuations and need a structured framework to support assumptions, methodology selection, and conclusions.

Attend for:

Evaluating biotech-specific value drivers:

Understand how development stage, clinical progress, intellectual property, and regulatory milestones shape cash flow projections and enterprise value across biotech life cycles.

Incorporating risk into valuation assumptions:

Learn how scientific, regulatory, and financing risks are reflected in probability-adjusted cash flows, discount rates, and cost of capital while maintaining analytical consistency.

Selecting and applying appropriate methodologies:

Review common biotech valuation approaches — income methods, scenario analysis, milestone-based models, or real options — aligned to company maturity and available data.

Supporting conclusions in professional practice:

Apply core valuation principles to biotech entities while addressing intangible assets, negative cash flows, and evolving risk profiles under audit and transaction scrutiny.

Leave with practical insights to enhance the quality, consistency, and defensibility of biotechnology valuations in advisory, financial reporting, and transaction settings.

Key Topics

• Biotechnology company valuation
• Probability‑adjusted cash flows
• Clinical and regulatory risk
• Scenario and milestone‑based modeling

Learning Outcomes

• Identify the key valuation drivers unique to biotechnology companies, including development stages, probability-adjusted cash flows, and regulatory milestones.
• Recognize how scientific, regulatory, and funding risks influence valuation assumptions and cost of capital.
• Recall common valuation approaches used in biotech, including scenario analysis, real options, and milestone-based modeling.
• Indicate core business valuation principles to biotech entities while addressing uncertainty, intangible assets, and limited operating histories.

Who Will Benefit

Valuation professionals performing or reviewing biotech valuations